PetLife Pharmaceuticals, Inc. (PetLife Pharma) has developed and is launching a new generation of potentiated veterinary cancer medications and nutraceuticals.

2. Escozine for Pets
New frontier in pet oncological treatment;
based on blue scorpion venom, which has been
used for years to to treat humans with cancer in
many countries
Revolutionary new drug, with proven ability to
reduce tumor size- no signs of toxicity or
complications observed during clinical use.
Can be easily administered, has healthy profit
margins, market acceptance will be quick,
translating to high sales growth
TM

3. The Problem
Pets are living longer than ever before, making them more
susceptible to developing cancer
 Cancer is the # 1 disease related cause of death for dogs
in the U.S.
 Cancer accounts for almost 50% of deaths in pets older
than 10 years
 Average costs to treat lymphoma in pets is $2,000-most
owners will rather watch their pets die than pursue
treatment
 1 in 4 dogs and 1 in 5 cats will develop cancer in their
lifetime
 Dogs get cancer at about the same rate as humans

4. Current Solutions
The most common treatment modalities used to combat cancer include: Surgical treatment, Chemotherapy, Radiation
Therapy and Immunotherapy.
PALLADIA is the first and only FDA-approved drug for canine cancer. While it is administered orally, it is still
technically chemotherapy. Side effects may include low white blood cell counts, diarrhea, vomiting, lethargy, fatigue,
and stomach ulceration.
Low response rate, “roughly 40% of dog with mast cell tumors will actually respond to the drug, while the majority
do not.”
(US National Library of Medicine National Institutes of Health)

6. Market Opportunity
In 2015, $60.28 billion was spent on
pets in the U.S.-26% on vet care
services
Breakdown: Spending on
Pets in 2015 ($ billions)
Pet Services: grooming & boarding 5.41
Food 23.05
Supplies/OTC Medicine 14.28
Vet Care 15.42
Live animal purchases 2.12

7. Market Opportunity
Current treatment methods are quite expensive and not
totally safe for pets
Initial visit, including diagnosis, discussion of
prognosis and a treatment plan
$200+
Major surgery to remove a tumour deep in the
body, or that requires reconstruction
$1500+
Chemotherapy (depends on the size of the dog)
ranges from $200 to $2,000 and up
Radiation therapy
ranges from $2,000 to $6,000
Pain medications
$25 to $50 a month.

8. CASE REPORT
I
Amount spent: $3,000
Posted by : Irena in Vancouver. CA,
Breed : Shepxgolden
Treatment : Owner Took no action/did
not seek further treatment
“My beautiful 12 years boy started vomiting and lost 20 lb. Bl.test 2x, great,
extray stomach , lungs great. Everything was great, but Sky was starved to
death in front my eyes. 2 months nightmare, cry from pain, cannot eat,
horrible. Ultrasound – mass tumor. Surgery, just open his belly told me
cancer is in lymp.nodes, have one months to live if most. My boy suffered so
much, so much , I let him go, when sleep on oper, table, hug him and let
him go. I cant let him suffer more. Was very, just like that, on and off 2
months.”
Prohibitive treatment costs means some owners
have no choice but to let their pets die rather than
seeking further treatment
Posted : March 3rd, 2011 08:03 PM
Cancer Type : Intestinal

9. Entertainment
NEYMAR BLACK
Escozine for Pets™
Introducing a new generation of HP
(high potency) veterinary cancer medications and nutraceuticals
Escozine for Pets™ Immunity
Booster
Escozine for Pets™ Supplements
and Nutraceuiticals

10. Escozine for Pets™
 Escozine™ for Pets ™ is a an innovative polarized,
potentiated bio-active peptide extracted from the
Blue Scorpion (Rhopularus Princeps)
 Induces apoptosis on a variety of cancer cells by a
pattern of DNA fragmentation
 It is based on the same-patented formula of
“Escozine” used for the treatment of cancer in
humans but is amplified through polarization
technology

11. 11
ESCOZINE FOR PETSTM inhibits blood
vessel growth (angiogenesis) in solid tumors.
Chlorotoxin blocks trans-membrane fluxes of
chlorine and regulates the adjusting of cell
growth, cell division and metastasis thereby
inducing tumor cell death (apoptosis). The
regulating of activity of the potassium (K+) 3-4
kDa, sodium (N+) 6-8 kDa and chloride (CL+)
voltgate ionic channels of the tumor cells leads
to growth arrest and causes cell death
(apoptosis); additionally, calcium dependent
potassium channels inhibit growth of other
cancer cells.
Innovation Therapeutics (2015). Review of Pre-clinical & Clinical data
and Scorpion Venom studies to further support clinical research &
development and registration of EscozineTM for Pet Life.

12. Escozine for Pets™
Escozine for Pets™ has a number of advantages
over current treatment regimens
 It can be used along with the traditional
forms of cancer treatment
 Sensitizes cancer cell resistance, thereby
increasing the efficacy of other drugs
used in treating the cancer in the animal.
 Has selective binding preferences with
malignant cells .
 Easy administering orally
 Cost effective

13. Escozine™ - A Breakthrough in Cancer
Documented clinical observations :
Reduction in pain
Enhancement of the recipient’s immune-system
Reduction of cancerous cell multiplication
Inhibition of new blood vessel formation from pre-existing cancerous
cells.
Improvement in quality of sleep
Reduction of inflammation
Dramatic reduction in the painful side-effects of chemotherapy and
radiation treatment
Improvement of appetite
Treatment and Prevention

14. Testimonials
It has now been almost 1 year and 5 months
since Bootsie's lung tumor diagnosis and 1 year
and 3 months of being on Escozine. I can't
thank the PetLife team and our vet, Dr Mitchell,
for making this and introducing it to us. I never
imagined she would still be with us today. If
you saw and interacted with Bootsie, you
wouldn't even know she had a tumor. She is an
up beat 16 year old cat (if there is such a thing)
who still loves sitting by the window sun
bathing and watching the birds, playing and
grooming her sisters (2 younger cats), and
snuggling with my husband and me.
anonymous
When we started Bootsie on the Escozine, we were
only hoping for it to help her lung tumor, however,
we think it may be helping other health conditions
she has. For the last 5 or so years now, Bootsie has
had kidney disease as well. Just 2 months ago (Oct
2015) when our doctor did a routine blood panel
check and urine check for her kidneys, her results
look the best they've been in a few years! We are
amazed at what this is doing for our baby's health.
For a then 15 year old cat who was given only 3
months to live now being 16 years old and making
it 1 year and 5 months past diagnosis is a true
miracle for us. Thanks again, Escozine!
anonymous

15. Testimonials
My 9-year-old toy poodle, Ophelia, developed multiple breast lumps. She's been
under the care of Dr. Joel Beth Mitchell of Aventura Animal Hospital and Resort.
Dr. Mitchell had to perform several extensive surgeries in order to remove them
all. Some biopsy results came back as low-grade carcinomas. We were
devastated. Those were very dark times. Dr. Mitchell, whose opinion we hold in
the highest regard, told us about Escozine. Some of her cancer patients who had
had grim prognoses in the past, are alive and well, and they are taking Escozine.
I was intrigued and encouraged, started reading a lot of literature on blue
scorpion venom and decided to try it. I'm so glad I did. Ophelia has recovered
remarkably well after very difficult surgeries. She's happy, full of energy and
does not show any signs of sickness anymore, thank G-d. Escozine is very easy
to administer. I only wish I could teach Ophelia to take it herself 😊. Very grateful
to Dr. Mitchell and Escozine team. Please continue your research and
development. It benefits animals and people as well. Thank you!
anonymous

16. Revenue Model
anonymous
Step 1. It is important that we first generate
interest in Escozine for PetsTM. We will generate
“buzz” through online articles, social media posts,
videos, and during animal events
Step 2. An animal specialist analyzes the needs of
the animal and prescribes Escozine for Pets alone
or in combination with other treament
Step 3: Management of pet condition. The pet is
monitored to ensure it is responding to treatment.
Step 4: Encourage owners whose pets have been
cured to spread word about Escozine

17. Revenue Growth to be Driven
 Expanding into new geographical markets. Each year, the company will open a new distribution center
in a strategic geographical market i.e. India, Latin America and others
 Ease of availability, cost effectiveness, easy administering, and aggressive brand building activities, will
drive sales increases at a fast pace, year on year
by New Customer Acquisitions

18. Competition
Conditionally approved by FDA in 2010, Kinavet-CA1®, is a tyrosine kinase inhibitor. It is used to treat mast
cell tumors, a common form of cancer that affects dogs. Kinavet-CA1® works in three ways: by blocking the
survival signal of the tumor cells, which may induce disappearance of the tumor, by preventing tumor growth
and preventing the spread of tumor cells (metastasis).
Competitor Description
Company/Drug
Paccal Vet®-CA1 has been granted conditional approval by the FDA for the treatment of: non-resectable stage
III, IV or V mammary carcinoma in dogs that have not received previous chemotherapy, or radiotherapy and
resectable and non-resectable squamous cell carcinoma in dogs that have not received previous
chemotherapy, or radiotherapy.
The only drug fully approved by the FDA for the treatment of cancer in canines is Palladia. Palladia is a
prescription-only therapy is used to treat grade II or III recurrent cutaneous mast cell tumors with or without
regional lymph node involvement. It works by blocking the activity of key receptors important in the
development of blood vessels that supply tumors, as well as receptors vital for tumor survival.

19. Competitive Advantage
Esozine for Pets™ will succeed against competition in a number of areas:
 Toxic cancer treatments for pets creates pent up demand for
PetLife’s non-invasive products.
 Patent Protection: PetLife has an exclusive license and rights to the
patent on Polarized Scorpion Venom
 Projected rapid sales growth and high gross margins: gives room
to adjust pricing for competitiveness
 Complementary treatment properties: Escozine for PetsTM can be
used as complementary treatment to chemotherapy drugs

20. Positioning
We will position Escozine for Pets™ in the
market as a non-invasive, cost effective ($249
cost of treatment per patient for each month)
drug in the pet oncology market
0
1
2
3
4
5
6
0 1 2 3 4 5 6
InvasivenessofTreatment
Cost of Treatment
Escozine
Surgery
Chemotherapy
Radiation Therapy

21. Marketing and Growth Strategy
Petlife’s primary marketing strategy is premised on building brand
awareness, and rapid penetration of strategic geographical markets.
Infomercials – Both online and offline to educate pet
owners about cancer risk in Pets.
Product bundling - market Escozine for Pets ™ and supplements as
treatments that symbiotically work with one another and can
effectively treat cancer in pets.
Multi-local launches-Running online and offline launches for each
new geographical market. This will help localize and establish PetLife’s
brand and products, and help improve Google search rankings

22. Partnership is our winning strategy
PetLife will sell Escozine for PetsTM to veterinarians using multiple respected
veterinarian centers of influence to promote the product.
Incentives will be provided to veterinarians to market the company’s products.
Independent veterinarians will voluntarily help the company conduct clinical trials of its
drugs.

23. 23
Financial Projections
2017 2018 2019 2020 2021
Sales $5,901,466 $47,410,201 $155,474,31 $316,923,10 $525,306,42
Gross Margin $5,022,989 $41,151,746 $136,431,05 $279,178,96 $464,313,68
Net Profit -$2,594,096 $14,802,094 $55,928,022 $116,005,26 $193,076,58
-$100,000
$0
$100,000
$200,000
$300,000
$400,000
$500,000
$600,000
Thousands
PetLife 5-Year Highlights
Escozine for Pets™ line of nutraceuticals
will launch in 2017, helping the business
immediately start generating cash.
High product margins and slow increase
in operating costs against sales.
High product margins, and fast revenue growth across all product categories (more than 100% sales growth in
the first three years) will see the company in a healthy cash positition

24. Investment Proposal
Petlife Pharma is seeking to raise $8.5 million through a private placement offering to fund the approval
and launch of Escozine for Pets™. The initial part of our raise is $400,000.
$6.88 million is earmarked for Multi-Center Clinical
Studies for Escozine for Pets™. These studies will
include testing of safety and toxicity as well as
determining appropriate doing parameters. It is
estimated that these studies can be completed in 18-
22 months
Once initial safety and toxicity studies are performed
the Company may consider applying for
Compassionate Use approval in certain animal
cancers. This could occur in a few as 9 months.

25. Investment Proposal
In return for $8.5 million, the company shall issue 17,000,000 shares to investors, which are equal to a
22.5% stake in the company after dilution.
Shareholder
Common
Shares
Common
Options
Phase One
$ Invested
Phase One
Shares
Phase
One
%
Fully Diluted
Shares
% Fully
Diluted
Irrevocable de Fidecomison
Confianza General De
Familiar Irrevocable 30,700,000 - $0 - 0.0% 30,700,000 40.6%
Grand Street Ventures 5,700,000 - $0 - 0.0% 5,700,000 7.5%
Shareholders with under
5% 11,083,652 - $0 - 0.0% 11,083,652 14.6%
Elite International Partners,
Inc. 11,203,125 - $0 - 0.0% 11,203,125 14.8%
Phase One Investors #1 - - $8,500,000 17,000,000 100.0% 17,000,000 22.5%
Total 58,686,777 - $8,500,000 17,000,000 100.0% 75,686,777 100.0%

26. Investment Proposal
-50.00
0.00
50.00
100.00
150.00
200.00
250.00
(2,000.0)
-
2,000.0
4,000.0
6,000.0
8,000.0
10,000.0
12,000.0
14,000.0
16,000.0
2017 2018 2019 2020 2021
SharePrice($)
MarketCap($million)
Value per Share ($) and Market Cap ($ million)
Value per Share Market Cap ($ million)
-60%
-40%
-20%
0%
20%
40%
60%
2017 2018 2019 2020 2021
Net Profit Margins
Net Profit Margin
High Free Cash Flow generating potential

27. Key Milestones

28. Sources
 DRESSLER, D. (2009). Palladia, First Dog Cancer Drug FDA Approved But Not Great. Retrieved May 29, 2016, from
http://www.dogcancerblog.com/blog/first-dog-cancer-drug-fda-approved-but-not-great/
 The Ins and Outs of Cancer in Pets. (2016). Retrieved May 29, 2016, from
http://www.vosrc.net/blog/the-ins-and-outs-of-cancer-in-pets/
 How Much Does Dog Cancer Treatment Cost? - CostHelper.com. (n.d.). Retrieved May 29, 2016, from
http://pets.costhelper.com/dog-cancer-treatment.html
 Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor
tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following
surgical excision. (2009, June/July). Retrieved May 29, 2016, from
http://www.ncbi.nlm.nih.gov/pubmed/19470739
 Pet Cancer Facts and Figures. (n.d.). Retrieved May 29, 2016, from
http://www.petinsurance.com/healthzone/pet-articles/pet-infographics/Pet-Cancer-Facts-and-Figures-
Infographic.aspx
 Pet Industry Market Size & Ownership Statistics. (n.d.). Retrieved May 29, 2016, from
http://www.americanpetproducts.org/press_industrytrends.asp
 Rusk, A., Dr. (n.d.). Cancer is the leading cause of death in dogs and cats. Retrieved May 29, 2016, from
http://www.vetcontact.com/en/art.php?a=773